Skip to main content

Primary IgAN

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Fosun Pharma
Fosun PharmaAustralia - Sydney
1 program
1
FXS6837 CapsulePhase 21 trial
Active Trials
NCT07750665Not Yet Recruiting60Est. Jan 2030

Trial Timeline

Clinical trial activity over time

2026
2027
2028
2029
2030
Fosun PharmaFXS6837 Capsule

Clinical Trials (1)

Total enrollment: 60 patients across 1 trials

FXS6837 for the Treatment for IgAN Patients(Longterm Study)

Start: Sep 2026Est. completion: Jan 203060 patients
Phase 2Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.